Home / Intelligence / Webinars / Virtual Demo | HTA Vision with GenAI
Available On Demand
Join Trinity Life Sciences for a virtual demo where value, access and pricing experts Max Hunt and Andreia Ribeiro will demonstrate Trinity HTA Vision, our cloud-based dashboard with GenAI capabilities.
It is not enough to know what the health technology assessment (HTA) decisions are and when they are made—with the landscape continually evolving, analogues and future impact cannot be judged by looking at decisions alone. Nuanced implications come from expert knowledge of countries/agencies, therapeutic areas and lifecycle stage.
Discover the power of HTA Vision with GenAI, where cutting-edge technology meets expert analysis. Our GenAI-powered tool swiftly extracts relevant information from HTAs and Trinity expert analyses, streamlining the information-gathering process within any therapeutic area or drug class.
Featuring
Max Hunt
Partner,
Evidence, Value, Access & Pricing
Andreia Ribeiro
Associate Principal,
Value, Access & Pricing
Complete the form below to view the on-demand demo.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Webinars
Part D in Peril: The Inconvenient Math of IRA Part D Redesign
August 14, 2025 | 12:00 – 12:45 PM ET
Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.
Sign Up Now
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]
Read More
Blog
Pricing and Access in Germany: Innovation and Strong Evidence Rewarded
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]
Read More